title: Stereoselective hydrolysis of xenobiotic esters by different cell lines from rat liver and hepatoma and its application to chiral prodrugs for designated growth suppression of cancer cells.
abstract: Stereoselectivity in the hydrolysis of racemic ethyl 2-phenylacetate derivatives by cultured cells of noncancerous cell lines from rat liver (BRL, BRL 3A, Clone 9, and ARLJ301-3), spontaneously or oncogene transformed rat liver cell lines (ARLJ301-3TR1, Anr4, Anr9-1, and Anr13-1), and cancer cell lines from rat hepatoma (H4-II-E, McARH7777, and MH1C1) and sarcoma (XC) was studied. A strong (R)-enantiomer preference was found in the hydrolysis of ethyl 2-hydroxy-(2c) and 2-methoxy-2-phenylacetate (3c) by the noncancerous and oncogene-transformed cells and an (S)-enantiomer preference for ethyl N-acylphenylalaninates with all the present cell lines. These inclinations were, however, not recognized with ethyl 2-methoxy-2-phenylpropanoate and ethyl N-difluoroacetyl- or N-trifluoroacetylphenylalaninate. Moreover, the R preference for 3c was reversed in the reaction by hepatoma cells. Thus, the stereoselectivity is influenced by both structure of acyl group and species of cell lines. The hepatoma cells were considerably different from the noncancerous or oncogene-transformed cells in stereoselectivity. This fact was consistent with the order of colony formation in soft agar cultures (index of malignancy) and the resemblance in actively stained esterase patterns in gel electrophoresis. The stereoselective hydrolysis leads to cell-specific activation of anticancer prodrugs. This has been confirmed for the first time by the stereoselectivity of Anr4 and H4-II-E cells in the hydrolysis of a chiral mustard ester, bis(2-chloroethyl)aminophenyl 2-methoxy-2-phenylacetate (14) and by the difference of IC50 values of (R)- and (S)-14 against the two cell lines.
authors.affiliation: National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ibaraki, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kageyama
authors.forename: Y
authors.initials: Y
authors.lastname: Yamazaki
authors.forename: A S
authors.initials: AS
authors.lastname: Afify
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Okuno
mesh_terms: D000362:Agar; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism*; D002417:Cattle; D002460:Cell Line; D002849:Chromatography, Gas; D002851:Chromatography, High Pressure Liquid; D004591:Electrophoresis, Polyacrylamide Gel; D004952:Esters / Q000378:metabolism; D006868:Hydrolysis; D008099:Liver / Q000378:metabolism*; D008114:Liver Neoplasms, Experimental / Q000378:metabolism*; D013058:Mass Spectrometry; D011355:Prodrugs / Q000378:metabolism*; D051381:Rats; D013237:Stereoisomerism; D014407:Tumor Cells, Cultured; D015262:Xenobiotics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D004952:Esters; D011355:Prodrugs; D015262:Xenobiotics; D000362:Agar